ALT stock forecast, quote, news & analysis
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases... Show more
Why Altimmune (ALT) Is Down -10% in the Last 30 Days
Key Takeaways
- ALT stock declined approximately -10% over the past 30 days, driven primarily by a recent $225 million public offering announcement that raised dilution concerns among investors.
- Over the past quarter, shares fell about -47%, reflecting pressure from dilutive financings, a wider-than-expected Q4 earnings loss, and mixed reception to clinical trial updates.
- Positive clinical progress on lead candidate pemvidutide, including Phase 3 plans for MASH (metabolic dysfunction-associated steatohepatitis), was overshadowed by funding needs typical in clinical-stage biotech.
- Analyst sentiment remains mostly bullish with high price targets, but dilution risks and cash burn continue to weigh on stock price.
- Biotech sector trends and macroeconomic caution around high-burn clinical companies contributed to the downward pressure.
Altimmune, Inc. (ALT) Company Overview and Market Position
Altimmune, Inc. is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics targeting serious liver diseases and immune modulation. Its lead product candidate, pemvidutide, is a GLP-1 (glucagon-like peptide-1)/glucagon dual receptor agonist in development for MASH, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company operates in the competitive obesity and liver disease sector, where dual agonists like pemvidutide aim to differentiate through superior weight loss and liver fat reduction profiles compared to single GLP-1 drugs.
Altimmune's business model relies on advancing pemvidutide through late-stage trials toward potential partnerships or approvals, with recent FDA Breakthrough Therapy Designation bolstering its position. Fundamentals, including a cash runway into 2028 post-recent raises, support clinical execution but expose the stock to dilution risks amid high R&D burn rates common in biotech stock analysis.
Altimmune, Inc. (ALT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ALT stock moved from approximately $3.24 to around $2.91, reflecting a -10% decline. The period was volatile and range-bound between $2.88 and $3.56 before a sharp drop triggered by the latest offering news.
In the past quarter, shares declined roughly -47% from about $5.50, exhibiting a downward trend punctuated by brief spikes on clinical news, followed by pullbacks on earnings and financing events. This price movement highlights trend-driven selling amid ongoing clinical and funding developments.
What Drove ALT Stock Price in the Last 30 Days
The primary catalyst for ALT's recent -10% drop was the April 22 announcement and pricing of a $225 million oversubscribed public offering of common stock and warrants at $2.999 per pre-funded warrant unit. Investors reacted negatively to the dilution impact, despite the funds extending the cash runway for pemvidutide's Phase 3 MASH trial, causing a 13-14% single-day plunge.
Prior to this, shares traded sideways with modest gains, buoyed by lingering optimism from March earnings updates on 48-week IMPACT Phase 2b data showing pemvidutide's efficacy in MASH resolution and fibrosis improvement. Analyst maintains, such as HC Wainwright's Buy rating and $25 target in mid-March, provided some support, but biotech sector weakness and profit-taking capped upside. Macro sentiment around high-interest rates limited risk appetite for development-stage names like ALT.
What Drove ALT Stock Performance Over the Last Quarter
ALT's -47% quarterly decline stemmed from a series of dilutive financings and earnings disappointment, outweighing clinical milestones. Key was the January $75 million registered direct offering, which fueled a post-announcement pullback from January highs near $6.20 amid dilution fears.
March 5 Q4 2025 earnings reported a wider-than-expected EPS loss of -$0.27, triggering a 17% drop despite positive 48-week pemvidutide data from the IMPACT trial. A Seeking Alpha downgrade to Sell on March 12 cited a projected $700 million funding gap without partnerships, amplifying concerns. Industry trends in GLP-1/MASH space showed competitive pressure, while institutional selling and broader biotech market trends under rates and inflation added downward force. Cumulative dilution from multiple raises eroded shareholder value, dominating the quarter's narrative.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms actively trading thousands of tickers across various markets. These curated bots represent the most relevant and high-performing strategies based on recent metrics like win rate, profit factor, and consistency across short-term, swing, or long-term timeframes. Each bot employs unique approaches, such as pattern recognition, momentum signals, or mean reversion, tailored to specific asset classes and volatility profiles. Investors can explore performance charts, backtests, and live results to identify bots aligning with their trading style. Check out the page to discover and deploy these cutting-edge tools today.
ALT Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor pemvidutide's Phase 3 MASH trial initiation expected in 2026, with biopsy endpoints critical for regulatory paths. Topline data from the RECLAIM Phase 2 AUD trial in Q3 2026 could validate expansion potential. Ongoing FDA interactions post-Breakthrough Designation and partnership discussions for pemvidutide commercialization are key catalysts. Macro factors like interest rates impacting biotech funding, plus cash burn versus runway (now bolstered to 2028), remain vital. Risks include trial setbacks, further dilution, or competitive advances in GLP-1 dual agonists.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
ALT in upward trend: price may ascend as a result of having broken its lower Bollinger Band on June 09, 2026
ALT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 44 cases where ALT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALT's RSI Indicator exited the oversold zone, of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 69 cases where ALT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on ALT as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ALT just turned positive on June 22, 2026. Looking at past instances where ALT's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ALT advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ALT entered a downward trend on June 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.003) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ALT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). ALT's P/S Ratio (10000.000) is very high in comparison to the industry average of (367.026).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals
Industry Biotechnology